PubMed · 2015 · 31 citations · 12 references
Life SciencesNeurologyPharmacotherapyClinical NeuroscienceNeurodegenerationNeuropharmacologyNeurodegenerative Disease PharmacotherapyParkinson DiseaseParkinson's Disease PharmacotherapyParkinson’s Disease Treatment
BACKGROUND: Electroconvulsive therapy is an established means to improve function in a variety of psychiatric and neurologic conditions, particularly for patients who remain treatment-refractory. Parkinson's disease is a neurodegenerative disorder that sometimes does not respond well to conventional pharmacotherapies. Reports have indicated that electroconvulsive therapy may be an effective and safe treatment for those patients with Parkinson's disease who are not optimally responding to first-line treatments. Despite these reports, however, electroconvulsive therapy is not often used by clinicians in patients with treatment-resistant Parkinson's disease, perhaps due to stigma, lack of knowledge regarding its safety and efficacy, and/or inability to predict the duration of therapeutic benefit. OBJECTIVE: Our objective was to determine if the available literature on ECT supports it as a safe and effective treatment option in patients with treatment-refractory Parkinson's disease. CONCLUSION: Motoric improvement induced by electroconvulsive therapy has been documented for decades in persons with Parkinson's disease. Efficacy and safety are reported following electroconvulsive therapy in people with Parkinson's disease who have sub-optimal response to medicines or experience the "on/off" phenomenon to L-dopa. Electroconvulsive therapy is an effective option for acute and maintenance treatment of Parkinson's disease in select patients. Inability to predict how long the beneficial effects of ECT therapy will last in patients with Parkinson's disease may be a reason why this treatment is underutilized by clinicians. More research is warranted to clarify parameters for application and duration of therapeutic benefit in individuals with difficult-to-treat Parkinson's disease.
12
Kenneth G. Lloyd, F Thuret, Andrzej Pilc · Journal of Pharmacology and Experimental Therapeutics · 1985 · 206 citations
Medicine, Neuroscience, Pharmacology +17
Effectiveness of ECT in Patients With Parkinsonism
Chris K. Moellentine, Teresa A. Rummans, J. Eric Ahlskog et al. · Journal of Neuropsychiatry · 1998 · 143 citations
Medicine, Neurology, Psychiatry +7
Chie Usui, Kotaro Hatta, Nagafumi Doi et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 2011 · 61 citations
Maintenance ECT in Parkinson's disease
P.A. Fall, Ann‐Kathrine Granérus · Journal of Neural Transmission · 1999 · 53 citations
Medicine, Neurology, Neuroscience +11